AstraZeneca (BUE:AZN) Cyclically Adjusted FCF per Share: ARS1,353.59 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:AZN AstraZeneca PLC BUE:AZN
79 GF Score
Price ARS64,075.00
GF Value ARS71,631.47
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted FCF per Share?

AstraZeneca BUE:AZN +0.39% 79 Cyclically Adjusted FCF per Share is ARS1,353.59 as of Jun. 2026. GuruFocus rates BUE:AZN with a GF Score™ of 79/100 and a GF Value™ of ARS71,631.47 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share for the three months ended in Jun. 2026 was ARS-227.877. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS1,353.59 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted FCF Growth Rate was 11.70% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AstraZeneca was 39.60% per year. The lowest was -15.00% per year. And the median was 5.20% per year.

As of today (2026-08-11), AstraZeneca's current stock price is ARS64075.00. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was ARS1,353.59. AstraZeneca's Cyclically Adjusted Price-to-FCF of today is 47.34.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 16.35. And the median was 50.81.


AstraZeneca  (BUE:AZN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=64075.00/1353.59
=47.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 16.35. And the median was 50.81.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AstraZeneca Cyclically Adjusted FCF per Share Related Terms


AstraZeneca Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted FCF per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.53 3.44 3.76 744.17 1,258.54

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 967.26 1,270.08 1,258.54 1,236.81 1,353.59

BUE:AZN vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.


BUE:AZN
79GF Score
AstraZeneca PLC BUE:AZN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-227.877/142.3000*142.3000
=-227.877

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 5.243 101.500 7.351
201612 16.516 102.200 22.996
201703 -3.617 102.700 -5.012
201706 -1.055 103.500 -1.450
201709 26.140 104.300 35.664
201712 6.706 105.000 9.088
201803 -7.538 105.100 -10.206
201806 -5.787 105.900 -7.776
201809 5.809 106.600 7.754
201812 54.013 107.100 71.765
201903 -35.360 107.000 -47.025
201906 -3.269 107.900 -4.311
201909 32.481 108.400 42.639
201912 45.069 108.500 59.109
202003 -11.204 108.600 -14.681
202006 3.285 108.800 4.296
202009 63.206 109.200 82.365
202012 77.475 109.400 100.774
202103 100.051 109.700 129.784
202106 38.740 111.400 49.486
202109 69.217 112.400 87.630
202112 45.258 114.700 56.148
202203 197.342 116.500 241.045
202206 54.380 120.500 64.218
202209 162.123 122.300 188.635
202212 198.171 125.300 225.058
202303 210.593 126.800 236.336
202306 190.000 129.400 208.941
202309 501.371 130.100 548.387
202312 331.630 130.500 361.616
202403 475.796 131.600 514.482
202406 1,387.451 133.000 1,484.468
202409 1,232.242 133.500 1,313.468
202412 1,262.177 135.100 1,329.443
202503 1,873.930 136.100 1,959.296
202506 1,114.126 138.400 1,145.521
202509 2,964.834 138.900 3,037.407
202512 979.732 139.900 996.539
202603 1,631.137 140.800 1,648.514
202606 -227.877 142.300 -227.877

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS1,353.59 mean?
AstraZeneca (BUE:AZN) has a Cyclically Adjusted FCF per Share of ARS1,353.59 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted FCF per Share too high?
AstraZeneca's current Cyclically Adjusted FCF per Share is ARS1,353.59. Overall, AstraZeneca has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted FCF per Share of ARS1,353.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted FCF per Share is ARS1,353.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (BUE:AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS71,631.47, compared to a current price of ARS64,075.00 — trading 10.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS1,353.59. AstraZeneca's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For AstraZeneca (BUE:AZN), the current Cyclically Adjusted FCF per Share is ARS1,353.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (BUE:AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of ARS64,075.00 is trading 10.5% below its estimated GF Value™ of ARS71,631.47. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for BUE:AZN:

  • Cyclically Adjusted FCF per Share: ARS1,353.59
  • GF Value™: ARS71,631.47 vs. price of ARS64,075.00 (10.5% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
79GF Score

Get the complete analysis for BUE:AZN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS64,075.00
Price
ARS71,631.47
GF Value